Company Focus
Ipsen
Latest Ipsen News
Biotechnology
French biotech Ipsen has entered an exclusive global licensing agreement with Biomunex Pharmaceuticals to develop BMX-502, a first-in-class T cell engager. 3 December 2024
Related News
Insights
Company Spotlight
A biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates.
Latest News & Features of interest to Ipsen
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Pharmaceutical
Denmark-based diabetes and obesity giant Novo Nordisk says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to establish a completely new production facility in Odense, Denmark. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Dutch biotech Pharming has announced a public cash offer to acquire all outstanding shares of Swedish firm Abliva for $66 million. 16 December 2024
Biotechnology
US biotech Checkpoint Therapeutics saw its shares jump more than 16% to $4.27 in after-hours trading on Friday, on the news of a first regulatory approval for the company. 16 December 2024
Biotechnology
News early in last week was dominated by presentations at the American Society of Hematology (ASH) meeting. Among these was AstraZeneca, which released new data on the benefits of adding venetoclax to its Calquence in chronic leukemia. Also showing at ASH was Sino-American biotech BeiGene, which focused its presentations on Brukinsa in leukemia and lymphoma. On the regulatory front, shares of Dutch gene therapy uniQure leapt on news that it had agreed a path forward for its Huntington’s candidate AMT-130. US biotech Q32 Bio released Ph IIA trial results for its bempikibart for alopecia areata that were described as “messy,” sending the firm’s shares plunging 75%. Keros Therapeutics was another big faller after the news that it was halting parts of its Phase II program with cibotercept in pulmonary hypertension. 15 December 2024
Biosimilars
The European Medicines Agency’s (EMA) human medicines committee (CHMP) adopted positive opinions for six biosimilar medicines at its December meeting. 14 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has published its annual report examining price increases for top-selling drugs in the USA, pointing to $815 million in prices hikes which it says are not clinically supported. 13 December 2024
Pharmaceutical
Italy-based CNS specialist Newron Pharmaceuticals has entered into a license agreement with EA Pharma, part of Japan’s Eisai to develop, manufacture and commercialize Newron’s innovative modulator of the excessive release of glutamate, evenamide, in Japan and other designated territories. 13 December 2024
Latest In Brief for Ipsen
Biotechnology
The Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for the treatment of early Alzheimer’s disease (AD). 5 December 2024
Latest Relevant Ones To Watch News
Venture capital firm BC Partners has entered into an agreement under which the private equity business at Goldman Sachs Alternatives will acquire a majority stake in Netherlands-based Synthon, from funds advised by BC Partners. 17 December 2024
16 December 2024
16 December 2024
12 December 2024
5 December 2024
29 November 2024
26 November 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze